Advertisement
Advertisement
INBX
Inhibrx Biosciences, Inc. Common Stock
92.38
USDSponsored
-0.73
-0.78%
Aug 11, 16:00 UTC -4
Closed
After-Market
92.31
-0.07
-0.08%
INBX Earnings Reports
Positive Surprise Ratio
INBX beat 11 of 23 last estimates.
48%
Next Report
Next Week
Date of Next Report
Aug 19, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$2.43
Implied change from Q1 26 (Revenue/ EPS)
--
/+13.02%
Implied change from Q2 25 (Revenue/ EPS)
-100.00%
/+31.35%
Inhibrx Biosciences, Inc. Common Stock earnings per share and revenue
On May 14, 2026, INBX reported earnings of -2.15 USD per share (EPS) for Q1 26, missing the estimate of -1.82 USD, resulting in a -17.96% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -6.47% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -2.43 USD, with revenue projected to reach -- USD, implying an increase of 13.02% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Bicara Therapeutics Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.84
Actual
-$0.82
Surprise
+3.18%
Septerna, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.28
Surprise
+33.26%
Autolus Therapeutics plc - ADR
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.22
Actual
-$0.15
Surprise
+31.82%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
$0.01
Actual
$0.05
Surprise
+400.00%
LENZ Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$1.09
Actual
-$1.02
Surprise
+6.95%
Codexis, Inc.
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.13
Surprise
+7.67%
Seer, Inc. Class A Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.31
Surprise
-12.56%
Legend Biotech Corporation - ADR
Report Date
Aug 11, 2026 For Q2 26
Estimate
$0.07
Actual
$0.09
Surprise
+17.80%
Mineralys Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.54
Actual
-$2.85
Surprise
-422.26%
Imunon, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.94
Actual
-$0.54
Surprise
+42.83%
FAQ
What were Inhibrx Biosciences, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Inhibrx Biosciences, Inc. Common Stock reported EPS of -$2.15, missing estimates by -17.96%, and revenue of $0.00, 0% as expectations.
How did the market react to Inhibrx Biosciences, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -6.47%, changed from $116.16 before the earnings release to $108.64 the day after.
When is Inhibrx Biosciences, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 19, 2026.
What are the forecasts for Inhibrx Biosciences, Inc. Common Stock's next earnings report?
Based on --
analysts, Inhibrx Biosciences, Inc. Common Stock is expected to report EPS of -$2.43 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement